

INFORMATIONAL LETTER NO. 2222-FFS

DATE: February 25, 2021

TO: All Iowa Medicaid Providers

APPLIES TO: Fee-for-Service (FFS)

FROM: Iowa Department of Human Services (DHS), Iowa Medicaid Enterprise (IME)

RE: Monoclonal Antibodies Information

EFFECTIVE: Upon Receipt

****This letter replaces Informational Letter 2218-FFS****

Recently, Bamlanivimab and Casirivimab/Imdevimab were granted emergency use authorization for the treatment of mild to moderate COVID-19 in outpatient settings.

The U.S. Department of Health and Human Services (HHS) is coordinating allocations of these medications, and sites must use the [direct order link¹](#) to order product directly from AmerisourceBergen. You may submit an order request at any time (i.e., orders are not restricted to a biweekly schedule). At this time, bamlanivimab and casirivimab/imdevimab continue to be available at no cost. Additional information on the direct order process can be found [here²](#). If you have any questions or issues with shipments, you can email c19therapies@amerisourcebergen.com.

Currently, there is no information on when Bamlanivimab/Etesevimab will be available. It is expected that Bamlanivimab and Etesevimab will only be available together and that Etesevimab will not be available by itself. Additional information on this treatment can be found [here³](#), including:

- [Fact Sheet for Patients, Parents, and Caregivers \(English\)⁴](#)
- [Fact Sheet for Patients, Parents, and Caregivers \(Spanish\)⁵](#)
- [Fact Sheet for Healthcare Providers⁶](#)

¹ [C19 Therapies Direct Order Request \(smartsheet.com\)](https://smartsheet.com)

² [Overview of direct order process for COVID-19 Therapeutics \(Fact Sheet\) \(phe.gov\)](#)

³ [Bamlanivimab and etesevimab EUA | Lilly COVID-19 Products](#)

⁴ [bam-and-ete-eua-factsheet-patient.pdf \(lilly.com\)](#)

⁵ [bam-and-ete-eua-factsheet-patient-span.pdf \(lilly.com\)](#)

⁶ [bam-and-ete-eua-factsheet-hcp.pdf \(lilly.com\)](#)

- [FDA Letter of Authorization⁷](#)

For more information on monoclonal antibodies, including webinar details, please visit [https://idph.iowa.gov/Emerging-Health-Issues/Novel-Coronavirus/Monoclonal-Antibody-Therapeutics/Information-for-Providers⁸](https://idph.iowa.gov/Emerging-Health-Issues/Novel-Coronavirus/Monoclonal-Antibody-Therapeutics/Information-for-Providers).

Please contact Cassie Kennedy at (515) 330-5755 or cassie.kennedy@idph.iowa.gov for questions on monoclonal antibodies.

⁷ [EUA 94 Bamlanivimab Etesevimab LOA \(clean 02092021\).pdf \(lilly.com\)](#)

⁸ [Novel Coronavirus - COVID-19 Monoclonal Antibody Therapeutics Information for Providers \(iowa.gov\)](#)